68Ga-PSMA PET/CT检出肾细胞癌转移灶:18F-FDG PET/CT漏诊
本文报告一例肾细胞癌(RCC)病例,18F-FDG与68Ga-PSMA PET/CT在肝转移灶均显示摄取增高,但肝下腹膜沉积灶仅在PSMA显像中显示摄取。由于背景摄取较低,PSMA对肝病灶显示更佳,提示68Ga-PSMA可能是RCC评估的潜在示踪剂。
要点
- RCC肝转移灶在18F-FDG与68Ga-PSMA PET/CT均见摄取增高。
- 肝下腹膜沉积灶仅在68Ga-PSMA PET/CT显示摄取。
- PSMA背景摄取较低,肝病灶显示优于FDG,提示其可能用于RCC评估。
核心结论
- 68Ga-PSMA PET/CT在肝下腹膜沉积灶检出方面优于18F-FDG PET/CT,且因背景摄取较低对肝病灶显示更佳,提示68Ga-PSMA可能是RCC评估的潜在示踪剂。
研究设计与样本
- 本文为病例报告,报告一例肾细胞癌(RCC)患者行18F-FDG与68Ga-PSMA PET/CT显像。
主要发现
- 18F-FDG与68Ga-PSMA PET/CT在肝转移灶均显示摄取增高。
- 肝下腹膜沉积灶仅在68Ga-PSMA PET/CT显示摄取。
- 因背景摄取较低,肝病灶在68Ga-PSMA PET/CT显示更佳。
临床怎么用
- 原文结论提示68Ga-PSMA可能是RCC评估的潜在示踪剂,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal cell carcinoma (RCC) accounts for ~2% of global cancers and deaths. Survival depends on initial staging and shows poor survival rate in metastatic disease. CT and MRI are used for evaluating RCC, and PET/CT is used for metastatic disease assessment. We report a case of RCC, where both 18F-FDG and 68Ga-PSMA PET/CT showed increased uptake in liver metastatic lesions; however, a subhepatic peritoneal deposit showed uptake only in PSMA. Also, liver lesions were seen better in PSMA owing to lesser background uptake, suggesting a possibility of 68Ga-PSMA being a potential tracer for RCC evaluation.
引用
- Jha S, Hemrom A, Shamim SA, et al. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT. Clin Nucl Med. 2023. PMID: 37133514. doi:10.1097/RLU.0000000000004648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。